tbuckley/cabot-search huggingface dataset:
Medical Biology: A Laboratory Manual of Bacteriology, Mycology, Immunology and Parasitology; Consisting of Experimental Guide, Interpretive Text, Atlas and Protocol Form.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Inhibition of cardiomyocytes late INa with ranolazine to prevent anthracyclines cardiotoxicity in experimental models in vitro and in vivo.
Authors: Nicola Maurea, Carmela Coppola, Giovanna Piscopo, Clemente Cipresso, Domenica Rea, Carlo G. Tocchetti, Michelino De Laurentiis, Claudio Arra, Rosario Vincenz Iaffaioli
Journal: Journal of Clinical Oncology (2013)

170 Background: Anthracyclines are first line drugs against cancer, but produce a well-known cardiomyopathy through multiple mechanisms, which also include Ca2+ overload due to reduced SERCA2a activity and inappropriate opening of the RyR2, and impaired myocardial energetics. Anthracyclines generate Reactive Oxigen and Nitrogen Species, posing the heart at increased demand for oxygen, thus setting the stage for a metabolic ischemia that also activates late INa, the target of ranolazine (RAN). Here, we aim at assessing whether RAN, diminishing intracellular Ca2+ through its inhibition of late INa, and enhancing myocardial glucose utilization (and/or reverting impairment of glucose utilization caused by chemotherapy) blunts anthracyclines cardiotoxicity. Methods: To assess for cardiotoxicity in vitro, rat H9C2 cardiomyoblasts were pretreated with RAN (0.1-1µM) for 72 hours and then treated with doxorubicin (DOX, 0.1 µM)for additional 24 hours. Cells counts were assessed by Trypan exclusion test. To evaluate cardiac function in vivo, fractional shortening (FS) and ejection fraction (EF) were measured by echocardiography in C57BL6 mice, 2-4 mo old, pretreated with RAN (370mg/kg/day, a dose comparable to the one used in humans) per os for 3 days. RAN was then administered for additional 7 days, alone and together with DOX (2.17mg/kg/day ip), according to our well established protocol. Results: After DOX, only 68% of the cells were viable. RAN alone did not affected cell survival, but blunted DOX toxicity, rescuing % cell survival to 87% (p=.01 vs DOX alone). In our in vivo studies, after 7 days with DOX, FS decreased to 50±2%, p=.002 vs 60±1% (sham), and EF to 81+2%, p=0.0001 vs 91+1% (sham). RAN alone did not change FS (59±2%) nor EF 89+1%. Interestingly, in mice treated with RAN and DOX, the reduction in cardiac function was milder: FS was 57±1%, EF was 89+1%, p=0.01 and 0.0009, vs DOX alone. Conclusions: RAN blunts DOX cardiotoxic effects in 2 different models, in vitro and in vivo. We plan to test RAN as a cardioprotective agent with other antineoplastic cardiotoxic drugs in our experimental models, and to better characterize the cardioprotective mechanisms of RAN in all these settings.
TONSILS AS PORTALS OF ENTRY OF TUBERCLE BACILLI.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Authors: Anu Sharma, Sumit K. Subudhi, Jorge Blando, Jorge Scutti, Luis Vence, Jennifer Wargo, James P. Allison, Antoni Ribas, Padmanee Sharma
Journal: Clinical Cancer Research (2018)

CTLA-4 was the first inhibitory immune checkpoint to be identified. Two mAbs, ipilimumab (IgG1) and tremelimumab (IgG2), which block the function of CTLA-4, have demonstrated durable clinical activity in a subset of patients with advanced solid malignancies by augmenting effector T-cell-mediated immune responses. Studies in mice suggest that anti-CTLA-4 mAbs may also selectively deplete intratumoral FOXP3+ regulatory T cells via an Fc-dependent mechanism. However, it is unclear whether the depletion of FOXP3+ cells occurs in patients with cancer treated with anti-CTLA-4 therapies.Quantitative IHC was used to evaluate the densities of intratumoral CD4+, CD8+, and FOXP3+ cells in stage-matched melanoma (n = 19), prostate cancer (n = 17), and bladder cancer (n = 9) samples treated with ipilimumab and in paired melanoma tumors (n = 18) treated with tremelimumab. These findings were corroborated with multiparametric mass cytometry analysis of tumor-infiltrating cells from paired fresh melanoma tumors (n = 5) treated with ipilimumab.Both ipilimumab and tremelimumab increase infiltration of intratumoral CD4+ and CD8+ cells without significantly changing or depleting FOXP3+ cells within the tumor microenvironment.Anti-CTLA-4 immunotherapy does not deplete FOXP3+ cells in human tumors, which suggests that their efficacy could be enhanced by modifying the Fc portions of the mAbs to enhance Fc-mediated depletion of intratumoral regulatory T cells.See related commentary by Quezada and Peggs, p. 1130.
FOUR PHASE BONE SCAN IMAGING TO PREDICT SKIN ULCER HEALING IN PATIENTS WITH PERIPHERAL VASCULAR DISEASE.
Authors: N. Alazraki, P. F. Lawrence, J. B. Syverud, F. Datz, A. Taylor
Journal: Clinical Nuclear Medicine (1983)

Departments of Radiology/Nuclear Medicine and Surgery, VA Medical Center, Salt Lake City, UT and University of Utah School of Medicine.
Book Review Climate and Evolution . By William Diller Matthew. Arranged by Edwin Harris Colbert. Preface by William King Gregory. With critical additions by the author and others and a bibliography of his scientific works by Charles Lewis Camp and Vertress Lawrence VanderHoof. Special Publications of the New York Academy of Sciences, Vol. 1. Second edition, revised and enlarged. 8°, cloth, 223 pp., with 33 illustrations and 5 tables. New York: New York Academy of Sciences, 1939. $2.00.
Journal: New England Journal of Medicine (1940)
Body weight and subsequent diabetes mellitus
Authors: J. B. O'Sullivan
Journal: JAMA (1982)

The ten- to 16-year predictive value of body weight for diabetes mellitus was evaluated prospectively in two groups of women with initially normal results of glucose tolerance tests. The incidence of diabetes in 602 high-risk (previous transient gestational glucose intolerance) participants was significantly higher for overweight subjects (46.7%) than for those of normal weight (25.6%). In 328 concurrently selected negative control subjects (without previous intolerance), the difference was not significant (4.5%<i>v</i>1.9%). Another definition of diabetes, indicating further deterioration, gave similar results, although high-risk overweight women had disproportionately higher incidence rates. Being overweight had no substantial predictive value for diabetes mellitus during this period unless the additional evidence for a high-risk classification was present. Among such persons at high risk, excess weight also predicted the severity of the subsequent diabetic condition. (<i>JAMA</i>1982;248:949-952)
Columbus and Vesalius—The Age of Discoverers
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Screening Test for HTLV-III (AIDS Agent) Antibodies
Authors: Stanley H. Weiss
Journal: JAMA (1985)

The third member of the human T-cell leukemia (lymphotrophic) retrovirus family (HTLV-III) is a newly discovered retrovirus that has been closely associated with the acquired immunodeficiency syndrome (AIDS). In our application of an enzyme-linked immunosorbent assay (ELISA) for HTLV-III antibodies, 72 (82%) of 88 patients with AIDS were positive, 14 (16%) were borderline, and two (2%) were negative. In contrast, only 1% of 297 volunteer blood donors were positive, 6% were borderline, and 93% were negative, demonstrating that this ELISA for HTLV-III antibodies is highly specific and sensitive for AIDS (excluding borderline results, 98.6% and 97.3%, respectively). Among persons at high risk for AIDS, 8% had borderline results, with positive and negative results readily distinguished as bimodal distributions that paralleled the temporal and geographic trends in AIDS. None of the 188 laboratory and health care employees working with patients with AIDS or their specimens were positive for HTLV-III antibodies, indicating that current precautions for health care workers appear adequate. This ELISA for HTLV-III antibodies will be a useful screening test among blood donors and populations at risk for AIDS, will aid in the diagnosis of suspected AIDS, and will help in defining the spectrum of diseases that are etiologically related to HTLV-III. (<i>JAMA</i>1985;253:221-225)
<i>Vibrio</i>Infections Down After California Restricts Oyster Sales
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A model for epidemiologic research
Authors: T. C. Doege
Journal: JAMA (1978)

Health sciences students should understand the fundamentals of epidemiologic methods that can lead to major advances in the treatment of disease. To this end, the research process is defined and a three-dimensional model that considers some basic elements of epidemiologic research—time, place, and strategy—is described. The strategies available to the investigator (descriptive, analytic, and experimental) and the possible time frames (retrospective, concurrent, and prospective) are illustrated in terms of field investigations that involve problems of infection, nutrition, dysplasia, metabolism, and cancer. It is believed that epidemiologic studies, no matter where they are performed, have certain features in common, especially those related to the elements of strategy and time. (<i>JAMA</i>239:328-330, 1978)
Adoption of international system of units for clinical chemistry
Journal: JAMA (1978)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Open Notes: Sharing Physician Notes With Patients
Authors: R. Hal Baker
Journal: Annals of Internal Medicine (2010)

Letters16 November 2010Open Notes: Sharing Physician Notes With PatientsR. Hal Baker, MDR. Hal Baker, MDFrom WellSpan Health, York, PA 17403.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-153-10-201011160-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I read with great interest Delbanco and colleagues' article (1) on sharing doctors' notes electronically with patients. In April 2007, the office in which I practice went live with our electronic health record, and we realized that writing outpatient instructions no longer made sense. For years, many of us had dictated notes in front of patients. So, at the noon meeting on the day we went live, we decided to give patients a copy of their notes at discharge, even though the notes contained a great deal more information than just instructions.Using voice-recognition software, we dictate ...Reference1. Delbanco T, Walker J, Darer JD, Elmore JG, Feldman HJ, Leveille SG, et al. Open notes: doctors and patients signing on. Ann Intern Med. 2010;153:121-5. [PMID: 20643992] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From WellSpan Health, York, PA 17403.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoOpen Notes: Doctors and Patients Signing On Tom Delbanco , Jan Walker , Jonathan D. Darer , Joann G. Elmore , Henry J. Feldman , Suzanne G. Leveille , James D. Ralston , Stephen E. Ross , Elisabeth Vodicka , and Valerie D. Weber Open Notes: Sharing Physician Notes With Patients David A. Nardone Metrics 16 November 2010Volume 153, Issue 10Page: 690KeywordsConflicts of interestElectronic medical recordsOutpatientsStomach ePublished: 16 November 2010 Issue Published: 16 November 2010 Copyright & PermissionsCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Bacterial prostatitis vs "prostatosis". A clinical and bacteriological study
Authors: E. M. Meares
Journal: JAMA (1973)

Chronic bacterial prostatitis, caused primarily by gram-negative bacteria, is a common cause of relapsing urinary tract infection. "Prostatosis," a common condition, is characterized by symptoms that simulate chronic bacterial prostatitis but the urine is sterile and the prostatic fluid cultures are negative. Historical and bacteriological data from 21 consecutive patients with chronic bacterial prostatitis were compared to similar data from 20 consecutive patients with prostatosis. Despite culture of the urethra, midstream urine, and expressed prostatic secretions for neisserial organisms, T-strain<i>Mycoplasma</i>organisms, aerobic bacteria, and anaerobic bacteria, no infectious agent was isolated in cases of prostatosis. Treatment of the two conditions is quite different.
Long-term insulin treatment in two nondiabetic patients
Authors: J. Asplund
Journal: JAMA (1981)

TODAY the diagnosis of insulindependent diabetes mellitus seldom presents problems. However, in two patients recently seen by us, renal glucosuria had been wrongly diagnosed as diabetes mellitus 33 and 51 years earlier. Throughout this period, treatment with long-acting insulin of an unpurified type had been administered, and this therapy was withdrawn. It was considered of interest to investigate the B-cell function in nondiabetic subjects after such a long period of insulin therapy. Since it has been suggested that the presence of insulin antibodies may be a factor in the development of diabetic microangiopathy,<sup>1</sup>we also searched for evidence of this condition. <h3>Report of Cases</h3><h3>Case 1.—</h3> In 1946, a 23-year-old man was found to have glucosuria, 1.5% to 4.0%; there was no ketonuria. Despite the absence of classic symptoms of diabetes mellitus and the recording of one normal glucose value, treatment was given, consisting of diet and administration of
Critical role of Fas/Fas ligand interaction in CD28-independent pathway of allogeneic murine hepatocyte rejection
Authors: T Kawahara
Journal: Hepatology (1997)

Cytolytic induction of T cells requires both the T-cell receptor (TCR)-mediated antigenic stimulation and the CD28-mediated co-stimulatory signal. Blockade of the interactions between CD28 and its ligands, CD80 and CD86, prolongs the survival of allografts in some transplantation models. However, we found that allogeneic hepatocytes were completely rejected within 7 days after intrasplenic transplantation, even when treated with monoclonal antibodies (mAbs) against CD80 and CD86 (anti-CD80/86). Recent studies have shown that there are two main mechanisms of T-cell-mediated cytotoxicity, perforin-based and Fas-based ones. It has been shown that the liver is highly sensitive to induction of apoptosis by an agonistic anti-Fas mAb. We then investigated the role of the Fas/Fas ligand (FasL) system in the CD28-independent allogeneic hepatocyte rejection. With the anti-CD80/86 mAb treatment, hepatocytes from C57BL/6 lpr/lpr (B6 lpr) mice, which express little Fas antigen, could survive for 7 days after intrasplenic transplantation, and hepatocytes from C57BL/6 (B6) mice could also survive for 7 days in the spleen of C3H/ He gld/gld (C3H gld) mice, which express no functional FasL. CD28-independent induction of cytotoxicity against allogeneic hepatocytes was not observed when the effector cells were derived from C3H gld mice. These results indicated that the Fas/FasL system plays a critical role in the CD28-independent pathway of allogeneic hepatocyte rejection.
In Reply:
Authors: G. Bacci, A. Longhi, C. Forni, P. Ruggieri, A. Briccoli, M. De Paolis, E. Setola
Journal: Journal of Clinical Oncology (2004)

In reply to the comments on our letter, 1 we accept the rectification of the total number of patients being 1,702 instead of 480; nonetheless, Bielack et al should have also specified that this number includes not only the patients with nonmetastatic osteosarcoma of the extremities who entered the neoadjuvant Cooperative Osteosarcoma Study Group (COSS) studies, 2 but also patients with tumors
TRAUMATIC ASPHYXIA.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Flaws in mortality data. The hazards of ignoring comorbid disease
Authors: S. Greenfield
Journal: JAMA (1988)

Recent public releases of hospital mortality data have sparked debate over methods to identify poor-quality care. We examined variations among hospitals in patient characteristics known independently to affect the risk of adverse outcomes and focused on patient comorbidity, defined as the state of health at admission apart from the primary diagnosis. Data from a study of 2935 incident cancer patients treated in seven Southern California hospitals revealed substantial variations among hospitals in age, cancer stage, and the burden of comorbid conditions. In the highest-ranked hospital, 17.9% of patients had high levels of comorbidity, compared with 9.3% in the lowest-ranked hospital. The three hospitals with the highest comorbidity were also identified as high-mortality outliers in a recent California report on hospital mortality rates. We conclude that comorbidity must be considered in any hospital quality assessment method based on patient outcome. If it is not considered, variations in referral and admission patterns may be misinterpreted as differences in hospital quality. (<i>JAMA</i>1988;260:2253-2255)